Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes

Oral antiplatelet agents (OAAs) can prevent further vascular events in cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical presentation of acute coronary syndromes (ACS) and clinical outcomes (death, myocardial infarction [MI]) is unclear. We studied and followed...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2004-10, Vol.110 (16), p.2361-2367
Main Authors: COLLET, J. P, MONTALESCOT, G, THOMAS, D, BLANCHET, B, TANGUY, M. L, GOLMARD, J. L, CHOUSSAT, R, BEYGUI, F, PAYOT, L, VIGNOLLES, N, METZGER, J. P
Format: Article
Language:English
Subjects:
Acute Disease
Administration, Oral
Aged
Aspirin - administration & dosage
Aspirin - adverse effects
Aspirin - therapeutic use
Biological and medical sciences
Blood and lymphatic vessels
Blood. Blood coagulation. Reticuloendothelial system
Cardiology. Vascular system
Cardiovascular Agents - therapeutic use
Cohort Studies
Coronary heart disease
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Drug Therapy, Combination
Electrocardiography
Female
Follow-Up Studies
Heart
Hemorrhage - chemically induced
Humans
Incidence
Male
Medical sciences
Middle Aged
Myocardial Infarction - epidemiology
Myocardial Infarction - etiology
Myocardial Ischemia - epidemiology
Myocardial Ischemia - etiology
Paris - epidemiology
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Prospective Studies
Risk Factors
Syndrome
Thrombosis - prevention & control
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oral antiplatelet agents (OAAs) can prevent further vascular events in cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical presentation of acute coronary syndromes (ACS) and clinical outcomes (death, myocardial infarction [MI]) is unclear. We studied and followed up for up to 30 days a cohort of 1358 consecutive patients admitted for a suspected ACS; of these, 930 were nonusers, 355 were prior users of OAA, and 73 had recently withdrawn OAA. Nonusers were at lower risk, more frequently presented with ST-elevation MI on admission, and more frequently had Q-wave MI at discharge than prior users (36.6% versus 17.5%, P
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.0000145171.89690.B4